Phio Pharmaceuticals

Coming – February 5

A Precision RNAi Approach to Treating Skin Cancer

Date and Time

February 5

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Phio Pharmaceuticals (NASDAQ: PHIO) has developed a differentiated, precision approach to treating skin cancer.

Phio’s core innovation is its INTASYL® siRNA technology, which silences cancer-driven gene responses that suppress the immune system. Unlike systemic immunotherapies, Phio’s lead program (PH-762) is injected directly into the tumor, resulting in a favorable safety profile with no serious toxicities reported to date.

Early clinical data in cutaneous squamous cell carcinoma (cSCC) are promising, with some patients achieving complete or near-complete tumor clearance. Notably, there is no FDA-approved drug for early-stage cSCC—the second most common solid tumor—where surgery remains the standard of care, creating a significant unmet need and market opportunity.

Phio has no debt, low manufacturing costs, strong patent protection into the 2040s, and an experienced leadership team.

Join our online event with Robert Bitterman, Phio Pharma President and CEO, for an overview of the company including their recently completed Phase 1B trial and their plans to advance into a either a Phase 2 or Phase 2B pivotal next-stage study.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.